Odonate Therapeutics

Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Odonate, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improve and extend the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.

NEW YORK, Oct. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the "Class Period"), of the important November 16, 2020 lead...

ROSEN, A LEADING LAW FIRM, Reminds Odonate Therapeutics, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ODT

New York, New York--(Newsfile Corp. - October 9, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the "Class Period"), of the important November 16, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Odonate investors under the federal securities laws.To join the Odonate class action,...

Rosen, Top Ranked Global Counsel, Reminds Odonate Therapeutics, Inc. Investors of Important Deadline in Securities Class Action - ODT

New York, New York--(Newsfile Corp. - October 2, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the "Class Period"), of the important November 16, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Odonate investors under the federal securities laws.To join the Odonate class action,...

Rosen, Leading Trial Attorneys, Reminds Odonate Therapeutics, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ODT

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the “Class Period”), of the important November 16, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Odonate investors under the federal securities laws. To join the Odonate class action, go to http://www.rosenlegal.com/cases-regis

ROSEN, A LEADING LAW FIRM, Reminds Odonate Therapeutics, Inc. Investors of Important November 16 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ODT

New York, New York--(Newsfile Corp. - September 24, 2020) -  Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc. ("Odonate" or the "Company") (NASDAQ: ODT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Odonate securities between December 7, 2017, and August 21, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by...

ODT Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Encourages Shareholders to Contact the Firm

New York, New York--(Newsfile Corp. - September 22, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Odonate Therapeutics, Inc. ("Odonate" or the "Company") (NASDAQ: ODT) of the November 16, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Odonate stock or

Odonate Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Odonate Therapeutics, Inc. To Contact The Firm

NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the...

ROSEN, A LEADING NATIONAL FIRM, Announces Filing of Securities Class Action Lawsuit Against Odonate Therapeutics, Inc. - ODT

SAN DIEGO--(BUSINESS WIRE)---- $ODT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) has filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between December 7, 2017 and August 21, 2020. Based in San Diego, California, Odonate is a pharmaceutical company that develops therapeutics for the treatment of cancer. The Company is developing tesetaxel, an oral chemotherapy.

Shareholder Alert: Robbins LLP Announces that Odonate Therapeutics, Inc. (ODT) is Being Sued for Misleading Shareholders

New York, New York--(Newsfile Corp. - September 18, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Odonate Therapeutics, Inc.

Rosen, Global Investor Counsel, Announces Filing of Securities Class Action Lawsuit Against Odonate Therapeutics, Inc. - ODT

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc. ("Odonate" or the "Company") (NASDAQ: ODT) and certain of its officers, on behalf of...

ODT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Odonate Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the “Class Period”).

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Odonate Therapeutics, Inc. – ODT

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Odonate Therapeutics, Inc.

Pomerantz Law Firm Announces the Filing of a Class Action against Odonate Therapeutics, Inc. and Certain Officers - ODT

A couple of factors appear to be at work after the company announced the pricing of a secondary stock offering.

Why Odonate Therapeutics Stock Is Soaring Today

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of an underwritten public offering of 5,614,036 shares of its common stock, offered at a price of $14.25 per share.

Odonate Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has commenced an underwritten public offering of shares of its common stock.

Odonate Therapeutics Announces Public Offering of Shares of Common Stock

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Odonate Therapeutics, Inc. (“Odonate” or the “Company”) (NASDAQ: ODT) complied with federal securities laws.

SHAREHOLDER ALERT: Investigation of Odonate Announced by Holzer & Holzer, LLC

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Odonate Therapeutics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Odonate Therapeutics, Inc. - ODT

Odonate Therapeutics (NASDAQ: ODT) shares were trading lower on Monday after the company announced the results from CONTESSA, a Phase 3 study of Tesetaxel, achieved the primary endpoint.

Why Odonate Therapeutics Is Trading Lower Today

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced positive top-line results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer (MBC).

Odonate Therapeutics Announces Positive Top-line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will hold a conference call on Monday, August 24, 2020 at 8:30 a.m.

Odonate Therapeutics to Hold Conference Call on Monday, August 24, 2020 at 8:30 a.m. ET

Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Odonate Therapeutics (ODT) Stock?

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2020.

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020

Odonate Therapeutics (ODT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Odonate Therapeutics (ODT) Stock Might be a Great Pick

Odonate Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Odonate Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Odonate Therapeutics, Inc. (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

News for Odonate Therapeutics Stock (ODT)